Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research note published on Sunday. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Stock Up 3.6 %

NASDAQ ONVO opened at $1.72 on Friday. The stock’s 50-day simple moving average is $4.14 and its two-hundred day simple moving average is $4.62. Organovo has a twelve month low of $1.56 and a twelve month high of $21.96. The company has a market capitalization of $2.93 million, a price-to-earnings ratio of -2.02 and a beta of 1.13.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($2.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.52) by $0.24. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.05 million. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. On average, equities analysts expect that Organovo will post -0.77 earnings per share for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.